Does growth hormone cause cancer
TL;DR: Given the experimental evidence that indicates GH/IGF‐1 provides an antiapoptotic environment that may favour survival of genetically damaged cells, longer‐term surveillance is necessary; over many years, even a subtle alteration in the environmental milieu in this direction, although not inducing cancer, could result in acceleration of carcinogenesis.
read more
Abstract: The ability of GH, via its mediator peptide IGF-1, to influence regulation of cellular growth has been the focus of much interest in recent years In this review, we will explore the association between GH and cancer Available experimental data support the suggestion that GH/IGF-1 status may influence neoplastic tissue growth Extensive epidemiological data exist that also support a link between GH/IGF-1 status and cancer risk Epidemiological studies of patients with acromegaly indicate an increased risk of colorectal cancer, although risk of other cancers is unproven, and a long-term follow-up study of children deficient in GH treated with pituitary-derived GH has indicated an increased risk of colorectal cancer Conversely, extensive studies of the outcome of GH replacement in childhood cancer survivors show no evidence of an excess of de novo cancers, and more recent surveillance of children and adults treated with GH has revealed no increase in observed cancer risk However, given the experimental evidence that indicates GH/IGF-1 provides an anti-apoptotic environment that may favour survival of genetically damaged cells, longer-term surveillance is necessary; over many years, even a subtle alteration in the environmental milieu in this direction, although not inducing cancer, could result in acceleration of carcinogenesis Finally, even if GH/IGF-1 therapy does result in a small increase in cancer risk compared to untreated patients with GH deficiency, it is likely that the eventual risk will be the same as the general population Such a restoration to normality will need to be balanced against the known morbidity of untreated GH deficiency
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Acromegaly: Re-thinking the cancer risk
TL;DR: The hypothesis that acromegaly, independent of hormone secretion, is a disease that heralds genetic and/or epigenetic alterations predisposing to cancer risk elsewhere is explored.
The value of IGF1 estimation in adults with GH deficiency
TL;DR: Analysis and interpretation of IGF1 status therefore represent a useful diagnostic tool especially in the younger adult patients with severe GHD and an essential measurement for monitoring GH replacement in all adults with GHD.
Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
Christopher J. Child,Daniel Conroy,Alan G. Zimmermann,Whitney W. Woodmansee,Eva Marie T Erfurth,Leslie L. Robison +5 more
TL;DR: There was no increased risk for all-site cancers: breast, prostate or colorectal primary cancers in GH-treated patients during HypoCCS, and GH treatment did not increase the risk of PA and CP recurrences.
In Vitro Functional Quality Characterization of NOTA-Modified Somatropins.
Nathalie Bracke,Han Yao,Evelien Wynendaele,Frederick Verbeke,Xiaolong Xu,Bert Gevaert,Alex Maes,Christophe Van de Wiele,Mike Sathekge,Sarah De Saeger,Bart De Spiegeleer +10 more
TL;DR: It is concluded that the NOTA-modified somatropins do not possess a significantly different in vitro functionality profile compared to unmodified Somatropin.
Early development of endocrine and metabolic consequences after treatment of central nervous system tumors in children.
TL;DR: Survivors of brain tumors suffer from numerous endocrine and metabolic consequences, majority of them developing within the first 5 years after brain tumor therapy, suggesting an active follow-up aiming for early diagnosis and therapy is essential for improvement of quality of life.
References
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Susan E. Hankinson,Walter C. Willett,Walter C. Willett,Graham A. Colditz,Graham A. Colditz,David J. Hunter,David J. Hunter,Dominique S. Michaud,Dominique S. Michaud,Bonnie Deroo,Bernard Rosner,Frank E. Speizer,Michael Pollak +12 more
TL;DR: A positive relation between circulating IGF-I concentration and risk of breast cancer was found among premenopausal but not postmenopausal women, and may be useful in the identification of women at high risk of Breast cancer and in the development of risk reduction strategies.
1.9K
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
Andrew G Renehan,Marcel Zwahlen,Christoph E. Minder,Sarah T O'Dwyer,Stephen M Shalet,Matthias Egger,Matthias Egger +6 more
TL;DR: Circulating concentrations of IGF-I and IGFBP-3 are associated with an increased risk of common cancers, but associations are modest and vary between sites.
1.7K
Insulin-like growth factors and neoplasia.
TL;DR: Converging results from epidemiological research and in vivo carcinogenesis models indicate that high levels of circulating IGF1 are associated with increased risk of several common cancers, and ongoing research seeks to clarify the mechanisms underlying these observations.
1.5K
The Somatomedin Hypothesis: 2001
TL;DR: In the liverspecific igf-1 gene-deleted mouse model, postnatal growth and development are normal despite the marked reduction in circulating IGF-I and IGF-binding protein levels; free IGF- I levels are normal.
1.2K
Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3
Jing Ma,Michael Pollak,Edward Giovannucci,June M. Chan,Yuzhen Tao,Charles H. Hennekens,Meir J. Stampfer +6 more
TL;DR: Ass associations of plasma levels of IGF-I and IGFBP-3 with the risk of colorectal cancer are suggested to be consistent during the first and the second 7-year follow-up intervals and among younger and older men.